- Izotropic Corp. (IZO) has engaged clinical research organization ICON plc to help prepare for its upcoming clinical study and submission for market authorization in the U.S.
- ICON’s medical device team will support multiple aspects of Izotropic’s clinical research study including contracting, start-up, data collection and analysis, and report writing for FDA submission
- Izotropic Corp. is the only publicly traded company commercializing a dedicated breast CT imaging platform for the more accurate detection and diagnosis of breast cancers
- Izotropic (IZO) is up 7.69 per cent, trading at C$0.42 at 11:45 am ET
Izotropic Corp. (IZO) has engaged ICON plc to help prepare for its upcoming clinical study and submission for market authorization in the U.S.
Clinical research organization ICON’s medical device team will support multiple aspects of Izotropic’s clinical research study, including contracting, start-up, data collection and analysis, and report writing for FDA submission.
Izotropic’s CEO, Dr. John McGraw, stated that Engaging ICON means that the company is confidently moving forward with its business plans to bring IzoView, its dedicated breast CT imaging platform, to market efficiently.
“We plan to run a multi-site study with leading U.S. hospitals which will help to expedite patient recruitment and broadens the clinical experience with IzoView. When operating a multi-site study, it is critical that the same set of processes and procedures from start to finish are followed at each site for every patient to mitigate exclusion and maintain data integrity, and ICON’s expertise enhances that capability.”
Izotropic Corp. is the only publicly traded company commercializing a dedicated breast CT imaging platform for the more accurate detection and diagnosis of breast cancers.
Izotropic (IZO) is up 7.69 per cent, trading at C$0.42 at 11:45 am ET.
